| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9e51cb26ccb205995a528a692a209ac4 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-0081
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-0066
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L33-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08H1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-726
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-0075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L33-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L33-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-726
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L33-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-00 |
| filingDate |
2007-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2009-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb64510dd4bc2f809c47c08424559a6a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2bdc7d1bae7b8064d25efd294abfa344
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a94a17530853d6f6e2a7cf14eef32df |
| publicationDate |
2009-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7504113-B2 |
| titleOfInvention |
Heparin-like compounds, their preparation and use to prevent arterial thrombosis associated with vascular injury and interventions |
| abstract |
The present invention is related to heparin-like compounds characterized by their capacity of inhibiting collagen-induced platelet aggregation in flowing whole blood and their use for prophylactic treatment of arterial thrombosis associated with vascular or microvascular injury and interventions. Said properties are related to a high coupling density of negatively charged heparin or heparin-like glycosaminoglycan molecules, present in multiple heparin or heparin-like glycosaminoglycans as well as in proteoglycans containing said multiple heparin or heparin-like glycosaminoglycans or lower-molecular-weight heparin or heparin-like glycosaminoglycans connected directly or through spacer/linker molecules to globular core molecules. Heparin-like compounds, with said properties are obtainable from mammalian mast cells, by tissue extraction or cell cultivation. The heparin-like compounds of the present invention can also be produced by synthetical, semisynthetical and/or biotechnological methods and they are useful for manufacturing preparations, means and devices for local or topical application in prophylactic treatment of arterial thrombosis and its sequelae. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009202607-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013095270-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9795629-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8415324-B2 |
| priorityDate |
1997-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |